Apogee Therapeutics Inc (APGE) Stock Price, Quote & News

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and e...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

Quantumup Mar. 17 at 12:05 PM

H.C. Wainwright⬇️ $EPRX $BMY AZN - AMGN $PHAT $APGE $CLDX H.C. Wainwright said—We reiterate our Buy rating on Eupraxia Pharmaceuticals (EPRX) and revise our price target to $11 (from $12) following the company's 4Q25 results and additional 52-week follow-up data from the RESOLVE trial evaluating EP-104Gl in eosinophilic esophagitis (EoE) While quarterly financials remain secondary for a clinical-stage company, the durability data continue to reinforce the differentiated profile of EP-104GI as a long-acting, localized steroid therapy, supporting the potential for infrequent dosing and improved adherence versus current treatment approaches Our price target revision reflects higher forward opex assumptions and dilution from the recent equity raise, partially offset by a higher probability of success for EP-104GI and a lower cost of capital in our model Importantly, the Phase 2b RESOLVE study remains on track for a 3Q26 topline readout, which we view as the next key catalyst for the program.

0 · Reply

Quantumup Mar. 17 at 10:33 AM

TD Cowen🏁 $NKTR at a Buy rating. $CRVS $APGE REGN $KYMR $CLDX Here's what TD Cowen had to say in its initiation report::Nektar is developing immunotherapies for use in l&l + oncology. Its lead asset, Rezpeg, is an IL-2 agonist targeting expansion and support of Tregs to broadly suppress autoimmune responses. We view Rezpeg's Ph2 AD data as compelling and expect it to gain meaningful market share. PoC is also in hand in alopecia. We model >$6B in combined sales, an NPV of $109/share, and are initiating at Buy.

0 · Reply

Quantumup Mar. 13 at 4:54 PM

Oppenheimer⬆️ $NKTR's PT to $140 from $115 and reiterated at an Outperform rating. $CRVS $APGE $AMGN LLY $CLDX Oppenheimer said—Following the impressive maintenance data for rezpeg in REZOLVE-AD, NKTR's 4Q25 update shifts attention back to the underappreciated opportunities in alopecia areata (AA) and T1D. On the AA front, NKTR will present data from the 36-week treatment period of the REZOLVE-AA study of rezpeg in a late-breaking oral session at the upcoming AAD meeting. Following that, topline data from the blinded 16-week extended treatment period will be reported in April, which could inform Ph3 study design. Meanwhile, initial data from TrialNet-sponsored Ph2 study of rezpeg in T1D will be reported in 2027 (potentially in the first half). With rezpeg's emerging competitive profile in AD, we believe these additional opportunities provide a reminder of rezpeg's pipeline-in-a-product potential. We update our model with $140 PT (vs. prior $115).

0 · Reply

Quantumup Mar. 11 at 8:06 PM

Raymond James (a/o 3/9) reiterated $EPRX at a Strong Buy rating and an $18 PT. $REGN - SNY $APGE BMY $TAK AZN - AMGN $PHAT Raymond James said in its note: Following our recent initiation of coverage and investor discussions thereafter, we are circling back to recap our thesis on EPRX, which we believe has among the best 2026 risk/reward setups in our coverage universe into Phase 2b RESOLVE data for EP-104GI in EoE expected in 2H26. Reiterate Strong Buy. Here's what else Raymond James had to say:

0 · Reply

StocktwitsEarnings Mar. 11 at 7:00 PM

$APGE Q4 '25 Earnings Results & Recap Apogee Therapeutics expects to report 16-week topline induction data from the APEX Phase 2 Part B trial in Q2 2026 and plans to initiate a Phase 3 trial in AD in H2 2026, aiming for a 2029 launch. Existing capital is sufficient until H2 2028.

0 · Reply

OfficialStocktwitsUser Mar. 10 at 5:54 PM

$APGE RSI: 64.12, MACD: 0.9172 Vol: 2.66, MA20: 70.19, MA50: 72.47 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

masonat Mar. 9 at 2:05 PM

$NKTR If you need a reminder on just how stupid the market is... NKTR down on PFE AD data, which is basically another dupixent "me too" and will be a direct competitor with $APGE, Dupi and all the other drugs with the same MOA. Yet APGE is flat and NKTR, with completely unique MOA, down big.

0 · Reply

IN0V8 Mar. 3 at 8:36 PM

$APGE Buy Wedbush raises target price to $95 from $90

0 · Reply

erevnon Mar. 3 at 4:21 PM

Wedbush maintains Apogee Therapeutics $APGE at Outperform and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

d_risk Mar. 2 at 4:33 PM

$APGE - Apogee Therapeutics Inc - 10K - Updated Risk Factors APGE’s risk profile expands around capital needs amid volatile biotech markets, heavier reliance on zumilokibart and other pipeline candidates with delayed trials, foreign CMO and tariff-driven supply-chain exposure, added device and generative AI risks, and growing uncertainty from shifting FDA leadership, trade policy, and tax law changes. #Biotechnology #ClinicalTrialDelays #SupplyChainRisk #RegulatoryUncertainty #CapitalMarketVolatility 🟢 Added 🟠 Removed https://d-risk.ai/APGE/10-K/2026-03-02

0 · Reply

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Feb 24, 2026, 7:30 AM EST - 21 days ago

Apogee Therapeutics to Participate in Upcoming March Conferences

Feb 5, 2026, 8:00 AM EST - 5 weeks ago

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 21, 2026, 10:29 AM EST - 7 weeks ago

Apogee Therapeutics: 2026 Inflection Point In Immunology

Jan 6, 2026, 2:28 PM EST - 2 months ago

Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript

Jan 6, 2026, 6:00 AM EST - 2 months ago

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Jan 5, 2026, 4:01 PM EST - 2 months ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Dec 3, 2025, 12:23 PM EST - 3 months ago

Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 7:10 AM EST - 4 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 7:00 AM EST - 4 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Nov 3, 2025, 7:30 AM EST - 4 months ago

Apogee Therapeutics to Participate in Upcoming Conferences

Oct 10, 2025, 4:01 PM EDT - 5 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Oct 9, 2025, 8:29 AM EDT - 5 months ago

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

HELE RACE

Oct 8, 2025, 9:52 PM EDT - 5 months ago

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Oct 8, 2025, 4:01 PM EDT - 5 months ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Sep 11, 2025, 7:30 AM EDT - 6 months ago

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Sep 3, 2025, 7:30 AM EDT - 6 months ago

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 4:50 PM EDT - 8 months ago

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Jul 7, 2025, 6:00 AM EDT - 9 months ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Jul 6, 2025, 6:00 PM EDT - 9 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

May 29, 2025, 7:30 AM EDT - 10 months ago

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 12, 2025, 4:04 PM EDT - 11 months ago

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class

May 12, 2025, 6:05 AM EDT - 11 months ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

May 12, 2025, 6:00 AM EDT - 11 months ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

May 1, 2025, 8:00 AM EDT - 11 months ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Apr 14, 2025, 8:04 AM EDT - 1 year ago

Apogee Therapeutics: Engineering Biologic Dominance

Mar 3, 2025, 12:16 PM EST - 1 year ago

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Mar 3, 2025, 6:05 AM EST - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Mar 3, 2025, 6:00 AM EST - 1 year ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Feb 28, 2025, 4:00 PM EST - 1 year ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Feb 25, 2025, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 7:00 AM EST - 1 year ago

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Jan 29, 2025, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Dec 2, 2024, 6:00 AM EST - 1 year ago

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Nov 29, 2024, 1:00 PM EST - 1 year ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Nov 18, 2024, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Nov 10, 2024, 9:55 AM EST - 1 year ago

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 4, 2024, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Sep 12, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Aug 12, 2024, 6:30 AM EDT - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Jun 18, 2024, 10:05 AM EDT - 1 year ago

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

May 28, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

May 23, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

May 13, 2024, 7:00 AM EDT - 2 years ago

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 2 years ago

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

Quantumup Mar. 17 at 12:05 PM

0 · Reply

Quantumup Mar. 17 at 10:33 AM

0 · Reply

Quantumup Mar. 13 at 4:54 PM

0 · Reply

Quantumup Mar. 11 at 8:06 PM

0 · Reply

StocktwitsEarnings Mar. 11 at 7:00 PM

0 · Reply

OfficialStocktwitsUser Mar. 10 at 5:54 PM

0 · Reply

masonat Mar. 9 at 2:05 PM

0 · Reply

IN0V8 Mar. 3 at 8:36 PM

$APGE Buy Wedbush raises target price to $95 from $90

0 · Reply

erevnon Mar. 3 at 4:21 PM

Wedbush maintains Apogee Therapeutics $APGE at Outperform and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

d_risk Mar. 2 at 4:33 PM

0 · Reply

ChessGM Mar. 2 at 1:00 PM

$APGE earnings https://youtu.be/542KmcGF1qU

0 · Reply

StockNews_Live Mar. 2 at 12:02 PM

$APGE Apogee Therapeutics provided pipeline progress and reported fourth quarter and full year 2025 financial results. The company announced positive APEX Phase 2 Part A results for zumilokibart in atopic d…

0 · Reply

JennyRowes Mar. 1 at 6:58 PM

$APGE competing program from $GENB

0 · Reply

BillionerOfKing Feb. 22 at 4:15 PM

$APGE Current Stock Price: $68.42 Contracts to trade: $70.0 APGE Mar 20 2026 Call Entry: $4.50 Exit: $6.86 ROI: 52% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AliciaNester280 Feb. 18 at 1:16 PM

$APGE Obesity-focused biotech with strong thematic tailwinds.

0 · Reply

SuperGreenToday Feb. 12 at 8:48 PM

$APGE Share Price: $69.93 Contract Selected: Jul 17, 2026 $70 Calls Buy Zone: $11.05 – $13.65 Target Zone: $20.58 – $25.15 Potential Upside: 76% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Feb. 10 at 5:39 PM

BTIG⬆️1H26 Top Pick $NKTR's PT to $151 and reiterated at Buy $CRVS $REGN - SNY $LLY KYMR $APGE Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2021276476335636938?s=20

0 · Reply

Quantumup Feb. 10 at 5:21 PM

William Blair⬆️ $NKTR to Outperform and provided its Take and Stock Thoughts. $CRVS $REGN - SNY $APGE $KYMR William Blair said: Rezpeg, continues to demonstrate deepening of response and durability with longer-term data—Re: durability, WB noted, there appears to be no meaningful deterioration of response when comparing the monthly dosing to the quarterly dosing—noted, there were no reported cases of conjunctivitis, erythema, oral ulcers, cardiovascular adverse events, or malignancies in the Phase 2 REZOLVE-AD study of rezpeg. Here's what else William Blair had to say: https://x.com/Quantumup1/status/2021272497862115591?s=20

0 · Reply

SuperGreenToday Feb. 2 at 8:38 PM

$APGE Share Price: $65.73 Contract Selected: Jul 17, 2026 $70 Calls Buy Zone: $9.35 – $11.55 Target Zone: $16.56 – $20.23 Potential Upside: 67% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 30 at 7:40 PM

$APGE Share Price: $66.59 Contract Selected: Jul 17, 2026 $70 Calls Buy Zone: $9.35 – $11.55 Target Zone: $17.27 – $21.10 Potential Upside: 74% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Fizz26 Jan. 30 at 5:05 PM

$DJIA $APGE garbage

0 · Reply

Fizz26 Jan. 30 at 4:23 PM

$DJIA $APGE getting dumped! I’m out

0 · Reply

Market Cap	5.00B
Revenue (ttm)	0.00
Net Income (ttm)	-255.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	651,400
Avg Vol	962,470
Day's Range	N/A - N/A
Shares Out	69.49M
Stochastic %K	26%
Beta	1.39
Analysts	Strong Sell
Price Target	$105.86